Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is really nice to see!!!
There is for me and the other longs who know what’s happening and are adding when we can. Follow the money. Seeing the CEO taking shares is a super strong indicator of where we are heading.
Thanks for the info. Good news! Also, the small note tells me that revs are picking up and CELZ just needing a small amount of notes to run the business. That is the first note since March 8th. I see that as good news and evidence that they are close to not needing note conversions much longer. Well on the way to self sufficiency.
Just as good IMO. If you worked and your boss comes to you and says, hey, do you want your paycheck or would you prefer the equivalent in company stock?
Obviously you would choose the one that is more valuable. Especially if you know the company is just getting started and growing and the shares will be worth far far more than cash.
Pretty cool option to have.
It also tells you that the shares are safe from the company rendering them useless by RS.
Not at ALL
ROTFLMAO
Awesome post. It’s a perfect explanation of what is happening.
Follow the money my friend. Smart trader :)
Pretty cool. They filed all the annual filing dating back to 2012. Something definitely brewing!
Imagine if you worked all month and your boss comes to you and says, hey Gint, do you want your paycheck or would you prefer the equivalent in company stock?
Obviously you would choose the one that is more valuable. Especially if you know the company is just getting started and growing and the shares will be worth far far more than cash.
Pretty cool option to have.
It also tells you that the shares are safe from the company rendering them useless by RS.
It’s a win/win for those who can see what’s happening.
What we also need to remember is that CELZ has NO control over the notes and warrants they have issued to commercialize CaverStem® and FemCelzTM. If you dissect the notes we all know, “worse case scenario” where the OS can top off at. Whether the note holders trickle them out like the previous months, or dump them faster like in June is not something they control, not the company. We also never know if they are being paid down. Things can change on a dime!
The biggest thing that has happened in a while is this form 4. It truly speaks volumes.
Carpe Noctem
LOL. I agree ;)
Bottom line, taking stock vs cash is a strong implication of health of the stock to me. He is lucky the PPS is so low. He only would have got 1,000,000 at .06 LOL.
Not sure. I think if they have taken shares as payment there would be form 4. BUT, that might only apply to Tim because he is over the 10% ownership threshold. If little ole me has millions of shares, I am sure they all do as well. They can buy whenever they want as long as they don’t go over a certain percentage of ownership. I think it’s 5% for you and I, and 10% for insiders. Then you have reporting rules. I may be wrong on that, but’s that’s how I remember it.
They will also have restrictions. I get them at my work. So many days before and after there is to be bigger news, we all get a notice that company shares are not to be bought or sold by the employees.
I agree. It’s laughable how low this is trading. What a golden opportunity. It is for the CEO. Personally, I am very jealous of his holdings.
Looks like Tim is holding (in this form 4) 83,940,283 shares of COMMON stock. Not preferred that would be protected in a RS. Strong circumstantial evidence that they have no plans to RS or that Tim thinks the shares are no value. All quite the opposite IMO. We will get there my fellow LONGS.
What’s super cool is they are more common shares. It does two BIG things. It tells you CELZ will NOT RS the common shares, and it proves I was right last month. Due to different filing requirements, the CEO is BUYING shares, not SELLING as some interpreted. Clears up a lot.
Same here runner. As long as they keep adding offices, we will be fine. Short term pain for long term gain. The only nice thing about the current situation is I know plenty of longs who are buying tons of shares as some fold up their tent and move along. It’s a marathon, not a sprint. July and August will reveal a lot IMO. I might even check out and come back then.
We will see a lot more of those in the coming weeks. What folks have to remember is nothing is 100%, well, except death and taxes, right?
CaverStem® has been wildly successful from what we have seen. Very high percentages of success.
Even in Gershman trial patients, ones who were younger, had serious issues, and who do not respond to PDE5 inhibitors, had a good success rate.
The trail results will be out this summer proving that, and more current real world, real patient testimonials will be out as well.
CELZ is definitely going through some serious growing pains, some self induced IMHO, but there will be no changing the outcome.
Anytime my friend. There are few of us left :)
Each market will close early at 1:00 p.m. (1:15 p.m. for eligible options) on Wednesday, July 3, 2019 and will be closed for the 4th.
CELZ does not have a history of diluting as much as they did in June.
In fact, the previous months were quite modest. It’s clear to me that they needed that cash for something.
They could be paying off the trial costs, or getting ready for the TV commercials, or hiring a spokesperson or a host of many other things as they commercialize CaverStem and FemCelz.
There is just too much going on with CELZ to think otherwise. We have seen updated filings and more activity on SM.
The Q2 is due in August and we all know it has to show increased revs.
There will be a lot happening in July IMO
The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.
CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PED5 inhibitors, CaverStem® and FemCelz is completely safe.
Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk, Sanderson and Hassid). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.
Two shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials have been published showing patients have been treated. Follow up testimonials will be published when ready.
CELZ added physicians California (Hassid), Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem® website as they come aboard. interest has been growing across the US and Europe. CELZ has been adding approximately 5 doctors per month in the most recent two months.
To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office/area to train.
Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.
Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos. The first ones were posted this week.
CELZ has started treating the first patients with the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program.
Over 50 domain names have been registered showing that more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.
CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the emails.
CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area.
U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.
Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.
A one-year trial has concluded and will PROVE the same results. You can watch for results here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14
CELZ is working on their paper for publication. The Principal Investigator is Dr. Jacob Rajfer, MD University of California, Los Angeles... top notch credentials. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only.
Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. Evidence of this are the scores of patients treated in Rome and NM. From these revenue streams, CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.
CELZ has Institutional Investors now, slowing dilution and providing much better terms as CELZ completes the commercialization phase. Two of the most recent notes that were issued in 2018 were renegotiated providing cash for operations.
CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz will generate. This has generated many calls to the vetted doctors.
CELZ anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz brands.
CaverStem® and FemCelz are just TWO of SEVERAL patents held by CMTH.
4 NEW patents were applied for in 2018.
CELZ anticipates commercialization of StemSpine in late 2019 or early 2020 bringing online a third revenue source.
Management has already successfully commercialized Medistem providing a large return on investment for the shareholders.
CaverStem®, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
CaverStem is now a REGISTERED TRADEMARK. Caverstem®
Absolutely!!!! Way too much happening!
Yup... Tells me they needed it :) Lots of irons in the fire. You called out a few of them, but there are many more.
a RM :)
Great post Hann-d. The longs are always pulling for you!
LAHO closed at .0009. Really getting ready to run. Solid RM about to happen IMO
We agree again. It’s a solid RM!!!
$LAHO looking really good right now!!
Agreed weesnel. As long as they keep moving forward with offices, I will keep adding.
Now that is cool
Excellent point. Always just a fear. Been threw too many LOL
I like the second paragraph. Something needs to give for sure.
Let’s just hope it’s not a RS!
Fully agree Apostle
I agree with your opinion :)
Good to see you here Chaka!
Agreed hubb. That is only for certain cases and like you said, temporary to let the stem cells work their magic for the permanent fix. There is no doubt the science behind the stem cells is solid.
It may be a bad analogy, but it’s like putting a cast on after orthopedic surgery. You need a cast until the permanent fix is healed up. Or wearing a sling to help your shoulder heal, you get my drift.
If folks want to pop pills and take the associated risks the rest of their lives, thats up to them. CaverStem offers an easy drug free alternative with excellent results. Simple as that.
I have been watching the numbers all year. They seem to post up on the second each month.